Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: topotecanBiological: hu14.18K322AProcedure: peripheral blood stem cell harvestProcedure: surgical resectionDrug: cisplatinDrug: etoposideDrug: doxorubicinDrug: vincristineDrug: busulfanDrug: melphalanBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyBiological: GM-CSFBiological: G-CSFDrug: mesnaDrug: levetiracetamBiological: interleukin-2Drug: IsotretinoinDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Non-Myeloablative Conditioning and Bone Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01850108
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷Saint-Louis Hospital, Paris, France
🇬🇧St Mary's Hospital, London, United Kingdom
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT01807611
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: MelphalanDrug: MesnaProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 150
- Registration Number
- NCT01798004
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT01783535
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 60
- Registration Number
- NCT01731886
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01670084
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
- Conditions
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT01652092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT01505569
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01490060
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.